Physician profile
Max E Quintana
NPI 1538392345
$2,978.10
in general payments reported to CMS, 2019-2025
21 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.23 · 2022: $26.97 · 2023: $592 · 2024: $1,090 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,890 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.01 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $585.08 | 2023-2025 | Wegovy, Ozempic, Saxenda |
| Abbott Laboratories | $498.05 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $406.50 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $291.35 | 2024-2025 | |
| Amgen INC. | $278.15 | 2023-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $216.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.45 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $110.67 | 2023-2025 | Farxiga |
| Gilead Sciences, INC. | $110.62 | 2023-2025 | |
| Pfizer INC. | $49.94 | 2023-2025 | |
| Viiv Healthcare Company | $47.23 | 2019 | |
| Dexcom, INC. | $42.71 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $37.91 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $31.69 | 2025 | Shingrix, Arexvy |
| Hologic Sales and Service, LLC | $28.88 | 2024 | Thinprep 2000 Processor, Aptima |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.97 | 2022 | |
| Dynavax Technologies Corporation | $25.59 | 2024 | Heplisav-B |
| Corcept Therapeutics | $25.28 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $19.45 | 2025 | |
| Currax Pharmaceuticals LLC | $16.91 | 2025 | Contrave |
| Phadia US INC. | $16.20 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Quintana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.